File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells

TitleVincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells
Authors
KeywordsBone marrow
Lymphoid leukemic cells
Mesenchymal stromal cell
Stromal suppression
Vincristine
Issue Date2010
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal
Citation
Leukemia And Lymphoma, 2010, v. 51 n. 3, p. 515-522 How to Cite?
AbstractBone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from l-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ALL cells. As a consequence, they can help to re-establish the cytotoxic potential of l-asparaginase on ALL cells even under MSCs support. In our study, pre-treating human MSCs with VCR but not IM, markedly reduced the protective capacity of MSCs. Furthermore, differential rescue effects were observed during addition of exogenous l-asparagine to co-culture with or without VCR pre-treatment. This supported the postulation that VCR could suppress the protective effect of MSCs to ALL cells by suppressing l-asparagine secretion. Our results suggested that the combined VCR and l-asparaginase treatment in ALL were synergistic and VCR can serve as an effective agent in suppressing the leukemic marrow microenvironment. © 2010 Informa Healthcare USA, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/163294
ISSN
2015 Impact Factor: 3.093
2015 SCImago Journal Rankings: 1.202
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, KLen_US
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorChan, GCFen_US
dc.date.accessioned2012-09-05T05:29:45Z-
dc.date.available2012-09-05T05:29:45Z-
dc.date.issued2010en_US
dc.identifier.citationLeukemia And Lymphoma, 2010, v. 51 n. 3, p. 515-522en_US
dc.identifier.issn1042-8194en_US
dc.identifier.urihttp://hdl.handle.net/10722/163294-
dc.description.abstractBone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from l-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ALL cells. As a consequence, they can help to re-establish the cytotoxic potential of l-asparaginase on ALL cells even under MSCs support. In our study, pre-treating human MSCs with VCR but not IM, markedly reduced the protective capacity of MSCs. Furthermore, differential rescue effects were observed during addition of exogenous l-asparagine to co-culture with or without VCR pre-treatment. This supported the postulation that VCR could suppress the protective effect of MSCs to ALL cells by suppressing l-asparagine secretion. Our results suggested that the combined VCR and l-asparaginase treatment in ALL were synergistic and VCR can serve as an effective agent in suppressing the leukemic marrow microenvironment. © 2010 Informa Healthcare USA, Inc.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lalen_US
dc.relation.ispartofLeukemia and Lymphomaen_US
dc.rightsLeukemia and Lymphoma. Copyright © Informa Healthcare.-
dc.subjectBone marrow-
dc.subjectLymphoid leukemic cells-
dc.subjectMesenchymal stromal cell-
dc.subjectStromal suppression-
dc.subjectVincristine-
dc.subject.meshAntineoplastic Agents - Pharmacologyen_US
dc.subject.meshAsparaginase - Metabolismen_US
dc.subject.meshBone Marrow Cells - Cytologyen_US
dc.subject.meshCoculture Techniquesen_US
dc.subject.meshDrug Screening Assays, Antitumoren_US
dc.subject.meshHumansen_US
dc.subject.meshInhibitory Concentration 50en_US
dc.subject.meshLeukemia, Lymphoid - Drug Therapy - Pathologyen_US
dc.subject.meshMesenchymal Stem Cells - Cytologyen_US
dc.subject.meshMesoderm - Metabolismen_US
dc.subject.meshModels, Biologicalen_US
dc.subject.meshPiperazines - Pharmacologyen_US
dc.subject.meshPyrimidines - Pharmacologyen_US
dc.subject.meshStromal Cells - Metabolismen_US
dc.subject.meshTetrazolium Salts - Pharmacologyen_US
dc.subject.meshVincristine - Pharmacologyen_US
dc.titleVincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cellsen_US
dc.typeArticleen_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.identifier.authorityChan, GCF=rp00431en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3109/10428190903406798en_US
dc.identifier.pmid19925050-
dc.identifier.scopuseid_2-s2.0-77249148314en_US
dc.identifier.hkuros179091-
dc.identifier.hkuros163812-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77249148314&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume51en_US
dc.identifier.issue3en_US
dc.identifier.spage515en_US
dc.identifier.epage522en_US
dc.identifier.isiWOS:000274878800021-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridFung, KL=36632178100en_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridChan, GCF=16160154400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats